Glycemia in newborns of hypertensive mothers according to maternal treatment by Darcie, Silvana et al.
244
REV. HOSP. CLÍN. FAC. MED. S. PAULO 59(5):244-250, 2004
From the Department of Pediatrics, Hospital
das Clínicas, Faculty of Medicine, University
of São Paulo - São Paulo/SP, Brazil.
E-mail: sdarcie@uol.com.br
Received for publication on
January 19, 2004.
ORIGINAL RESEARCH
GLYCEMIA IN NEWBORNS OF HYPERTENSIVE
MOTHERS ACCORDING TO MATERNAL TREATMENT
Silvana Darcie, Cléa R. Leone, Valdenise M. L. T. Calil, Elizete P. Prescinotti,
Soubhi Kahhale and Marcelo Zugaib
DARCIE S et al. Glycemia in newborns of hypertensive mothers according to maternal treatment. Rev. Hosp. Clín. Fac. Med.
S. Paulo 59(5):244-250, 2004.
PURPOSE: To evaluate the evolution of glycemic levels in newborns of hypertensive mothers according to maternal
treatment.
METHODS: Prospective randomized study, including 93 newborns of mothers treated with isradipine (n = 39), atenolol
(n = 40), or low sodium diet (control group – n=14). Glycemia was determined at birth (mother and newborn by the oxidase
glucose method) and in the 1st, 3rd, 6th, 12th, and 24th hours after birth (newborn by a test strip method). The evolution of
glycemia was analyzed in each group (Friedman test). The groups were compared regarding glycemia (Kruskall-Wallis test),
and linear regression models were constructed for the analyses (independent variable = maternal glycemia; dependent
variables = umbilical cord, 3rd, and 6th hour glycemia).
RESULTS: There were no statistically significant differences among the mean blood glucose levels of the 3 groups in
any of the assessments. There was a correlation between maternal and umbilical cord blood glucose in the isradipine (r =
0.61; P <.05) and control (r = 0.84; P <.05) groups. Regarding glycemia levels of the mothers and newborns in the third and
sixth hours postpartum, this correlation was present only in the control group (maternal x third hour: r = 0.65; P <.05;
maternal x sixth hour: r = 0.68; P <.05). There were no correlations in the atenolol group. Hypoglycemia was detected in
51.3% of the isradipine group, 60% of the atenolol group, and 35.7% of the control group, and it was more frequent in the
first hour postpartum in all groups.
CONCLUSIONS: The results suggest a similar effect of the 3 types of treatment upon newborn glycemia. The correlation
analysis suggests that isradipine could have effects upon newborn glycemia only after birth (correlation only in umbilical
cord blood), whereas atenolol could act earlier (there was no correlation at any moment). The results also point to the need
for glycemic control from the first hour postpartum of newborns of hypertensive mothers whether they have or have not
undergone treatment with antihypertensive drugs.
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Hypertension during gestation
may be considered not only a disorder
but also a maternal response to an un-
derlying disease. It is usually the first
signal of a placental dysfunction, and
therefore it may be used as a risk pre-
dictor.1,2
The elevation of blood pressure in
gestation that is a consequence of a
pre-existent arterial hypertension or
preeclampsia is associated with severe
fetal-maternal risks. For the mother,
there is the risk of eclampsia, HELLP
syndrome with multiple organ failure,
cerebral hemorrhage, and death. For
the fetus, there is an increasing risk of
an intrauterine growth restriction, pre-
mature birth, abruptio placenta, and
fetal death.1-3
However, since antihypertensive
treatment may reduce the need for in-
terrupting gestation, fetal maturity
may be obtained, with a reduction of
neonatal loss as a consequence.1,4
There are several drugs that act upon
blood pressure control, with different re-
sponses. Some exert central action, oth-
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ers alter cardiac output, others affect pe-
ripheral vascular resistance, and others
inhibit angiotensin-converting enzyme.1
Some treatment modalities seem to
be favorable, although other drugs
have undesirable side effects. Atenolol,
a beta-blocker, is a drug used to con-
trol the blood pressure levels during
gestation, mainly in the patient who
has an elevated cardiac output. How-
ever, there are reports of abnormalities
in the fetal heart rate when this drug
is used. The use of beta-blockers in
gestation is also associated with
hypoglycemia, bradycardia, and hypo-
tension in some newborns.1,5
Among the treatment modalities,
isradipine is a dihydropyridine cal-
cium antagonist that acts as a calcium
channel blocker (classified as a drug
that acts upon peripheral vascular re-
sistance). Isradipene has been found to
be well-tolerated, free from side effects
upon the uteroplacental circulation
and the fetal hemodynamics, present-
ing a low tocolytic effect, reducing
blood pressure in non-proteinuric hy-
pertensive women.6,7,8,9
Considering these characteristics of
isradipine, a study was developed with
the aim of evaluating its effects on the
evolution of glycemia levels in
newborns of pregnant women who
have arterial hypertension , comparing
it to the use of atenolol and with situ-
ations where the blood pressure con-
trol was done without using antihyper-
tensive medications.
Test Population and Methodology
Test population
The test population comprised 93
newborns admitted in the Nursery Annex
to the Maternity, Neonatal Pediatrics
Service, Children’s Institute “Prof. Pedro
de Alcântara”, Faculty of Medicine,
University of São Paulo (BAM), from
06/01/1994 to 03/19/1997, who fulfilled
the following inclusion criteria:
1) Newborn of a mother with arte-
rial hypertension defined as a diastolic
blood pressure (Korotkoff phase 4)
equal to or higher than 90 mmHg, meas-
ured on the left arm at the heart level,
after at least 10 minutes of resting,
seated, or in dorsal decubitus position
with adequate cuff on 2 occasions at in-
tervals of a minimum of 6 hours;
2) The maternal hypertension diag-
nosis was specific hypertensive dis-
ease of pregnancy (SHDP) or chronic
arterial hypertension (CAH) and super-
imposed SHDP, treated with isradipine,
atenolol, or without antihypertensive
medication with only a low sodium
diet (noting that the pregnant women
who received drugs also were pre-
scribed a low sodium diet);
3) The mother had been undergo-
ing the treatment for at least 2 weeks
before the delivery (a previous study
with pregnant women showed a statis-
tically significant reduction in the
blood pressure levels in a week after
the beginning of the use of drugs.10
Also, the group that received only the
diet intervention must have been on
the low sodium diet for a minimum
period of 2 weeks);
4) The newborn was a result of a
singleton pregnancy;
5) The pregnant woman had given
post-information consent.
Exclusion criteria:
1) The mother had a previous fetal
loss, especially without explanation;
2) The mother had another pathol-
ogy, such as cardiopathy, hepatopathy,
hemopathy, diabetes, or pneumopathy;
3) The mother had been taking
other medications that could interfere
with the metabolism of carbohydrates
in the newborn.
The study was approved by the
Ethics Committee in Research of the
Institution.
Methodology
This was a randomized, longitudi-
nal, prospective study comparing 3
groups of patients according to the
type of maternal treatment:
Group 1: 39 newborns of hyperten-
sive mothers treated with isradipine (5
mg twice a day);
Group 2: 40 newborns of hyperten-
sive mothers treated with atenolol (50
mg twice a day);
Control group: 14 newborns of
mothers whose hypertension was con-
trolled with diet only.
Study Design
All newborns included in the study
were evaluated at birth through the use
of the Apgar score at the first and fifth
minutes postpartum, and birth weight
in relationship to gestational age was
evaluated according to Ramos intrau-
terine growth curve.11
Glycemia was determined at birth in
the mother and in the newborn (through
venous blood assessment of the umbili-
cal cord) and then successively in the
newborn in the 1st, 3rd, 6th, 12th, and 24th
hours postpartum. Immediately after col-
lection, the blood sample was sent to the
laboratory for analysis.
The glucose oxidase method was
used for the maternal and newborn
glycemias at birth, and the DextrostixÒ
strip method test (analyzed by the same
GlucometerÒ machine throughout the
study) for the 1st, 3rd, 6th, 12th, and 24th
hour samples from the newborn.
The newborns were preferentially
breastfed, and in cases where this was
not possible, were fed with a formula
for term newborns after the first
6 hours postpartum.
Hypoglycemia was considered to
be blood glycemia values less than
40 mg/dL.
Statistical analysis
The 3 groups were analyzed among
themselves, at every time point of assess-
ment by analysis of variance (ANOVA),
in which the Kruskal-Wallis test (one-
way ANOVA test) was used. The evolu-
tion of glycemic levels was evaluated by
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the Friedman repeated measure test
(one-way ANOVA test) in each group.
Linear regression models were con-
structed for the glycemic concentra-
tions, considering maternal glycemia
as an independent variable; dependent
variables were the glycemias of the
umbilical cord and of the newborn in
the third and sixth hours postpartum.
Fisher’s exact test was used for
comparing the proportions.
The significance level was set as
P <05.
RESULTS
Ninety-three newborns that ful-
filled the inclusion criteria were in-
cluded in the study. However, only the
newborns with usable test results were
included in the statistical evaluation.
There was no difference among the
groups regarding gestational age,
weight, classification, Apgar, sex,
color, and type of delivery. (Table 1)
Differences related to the glycemic
levels of the mother and the newborn
were not observed among the groups,
and there were no differences among
the glycemic levels regarding any of
the determinations at any time point
for any group as shown in Table 2.
Figure 1 shows the evolution of
glycemic levels with time in each group.
Figures 2 and 3 show the correla-
tion between the maternal and umbili-
cal cord glycemias in the isradipine
Table 1 - Characteristics of the newborn.
Isradipine Atenolol Control Test (Kuskal-Wallis)
GESTATIONAL AGE n = 39 n = 40 n = 14 χ2
2
 = 1.79
µ (weeks/days) ± sd(days) 37/3 ± 13.2 37/3 ± 15.2 38/6 ± 13.6 (ns)
WEIGHT n = 39 n = 40 n = 14 χ2
2
 = 3.78
µ(kg) ± sd 2.91 ± 0.7 2.63 ± 0.6 2.97 ± 0.6 (ns)
CLASSIFICATION n = 39 n = 40 n = 13 χ2
2
 = 0.71
AIG - n (%) 33 (84.6) 31 (77.5) 12 (85.7) (ns)
PIG -n (%) 3 (7.7) 8 (20) 2 (14.3)
GIG -n (%) 3 (7.7) 1 (2.5) 0
µ ± sd 13.0 ± 17.3 13.3 ± 15.7 4.7 ± 6.4
APGAR first. MINUTE n = 36 n = 40 n = 14 χ2
2
 = 1.00
0-3 - n (%) 2 (5.6) 2 (5.0) - (ns)
4-6 - n (%) 1 (2.8) 2 (5.0) 2 (14.3)
7-10 - n (%) 33 (91.7) 36 (90.0) 12 (85.7)
µ ± sd 7.8 ± 1.8 8.0 ± 1.6 7.9 ( ± 1.4)
APGAR fifth. MINUTE n = 39 n = 40 n = 14 χ2
2
 = 2.25
7 - n (%) - 1 (2.5) - (ns)
8 - n (%) 2 (5.1) 3 (7.5) -
9 - n (%) 30 (76.9) 23 (57.5) 10 (71.4)
10 - n (%) 7 (17.9) 13 (32.5) 4 (28.6)
µ ± sd 9.1 ± 0.5 9.2 ± 0.7 9.3 ± 0.5
SEX n = 39 n = 40 n = 14 χ2
2
 = 0.10
Male-n (%) 21 (53.8) 22 (55.0)  7 (50.0) (ns)
Female-n (%) 18 (46.2) 18 (45.0) 7 (50.0)
COLOR n = 39 n = 39 n = 14 (white vs black
White-n (%) 10 (25.6) 14 (35.9) 7 (50.0) + dark)
Black-n (%) 6 (15.4) 6 (15.4) 1 (7.1) χ2
2
 = 2.88
Dark-n (%) 23 (59.0) 19 (48.7) 6 (42.9) (ns)
TYPE OF DELIVERY n = 39 n = 40 n = 14 (normal ±
Cesarean-n (%) 28 (71.8) 30 (75.0) 8 (57.1) forceps vs
Forceps-n (%) 5 (12.8) 4 (10.0) 2 (14.3) cesarean)
Normal-n (%) 6 (15.4) 6 (15.0) 4 (28.6) χ2
2
 = 1.63 (ns)
group and in the control group respec-
tively.
The glycemic values in each group
according to the assessment time point
are listed in Table 3.
The hypoglycemic episodes that
occurred during the first 24 hours post-
partum are shown in Figure 4, and the
distribution of these episodes per
group is shown in Figure 5.
Figure 6 shows the number of




hematologic effects due to the use of
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Table 2 - Maternal and newborn glycemic levels (mg/dL).
Isradipine Atenolol Control Test (Kruskal-Wallis)
Maternal glycemia n = 37 n = 33 n = 13 χ2
2
 = 0.95
µ ± sd 104.1 ± 42.2 110.9 ± 43.2 114.0 ± 33.8 (ns)
Umbilical Cord glycemia n = 38 n = 38 n = 12 χ2
2
 = 4.01
µ ± sd 80.5 ± 32.3 78.9 ± 30.7 97.4 ± 31.7 (ns)
Glycemia 1st h (newborn) n = 35 n = 36 n = 9 χ2
2
 = 1.47
µ ± sd 45.0 ± 23.1 37.6 ± 13.3 53.9 ± 18.0 (ns)
Glycemia 3rd h (newborn) n = 36 n = 37 n = 11 χ2
2
 = 2.95
µ ± sd 56.0 ± 24.8 53.4 ± 22.7 68.5 ± 39.6 (ns)
Glycemia 6th h (newborn) n = 34 n = 36 n = 13 χ2
2
 = 1.86
µ ± sd 58.8 ± 25.2 55.9 ± 22.3 52.0 ± 15.8 (ns)
Glycemia 12th h (newborn) n = 37 n = 39 n = 12 χ2
2
 = 2.19
µ ± sd 61.4 ± 24.9 55.7 ± 22.8 53.3 ± 18.1 (ns)
Glycemia 24th h (newborn) n = 36 n = 38 n = 14 χ2
2
 = 1.65








(P <.001) (P <.001) (P <.01)
Figure 1 - Evolution of glycemia during the
study.
Figure 2 - Correlation between maternal and the umbilical cord glycemia
in the isradipine group.
Figure 3 - Correlation between maternal and the umbilical cord glycemia
in the control group.
isradipine have been published in the
medical literature.12,13,14,15,16 The drug
has been shown to have a good anti-
hypertensive effect in patients who
have nonproteinuric hypertension dur-
ing gestation without modifying pla-
cental circulation,6,7,8,9 and its effi-
ciency and good tolerance in patients
who have essential hypertension has
been demonstrated.17 However, con-
cerns about the effects on the fetus
have been raised, since isradipine can
pass through the placenta, although
the concentration has been found to be
low in the fetus.18 Despite these con-
cerns, calcium channel blockers have
been described as safe drugs and free
of side effects to the fetus when used
during gestation to control arterial hy-
pertension.1,19 But data is scarce con-
cerning the possible hypoglycemic ef-
fect on the fetus of isradipine, a new
generation calcium channel blocker.
The present study demonstrates
that all treatments were safe regarding
the evolution of glycemic levels, since
there was no difference between the
treated and the control groups for any
assessment (Table 2).
As for the glycemia evolution with
time in each study group, a statistically
significant difference was verified
among the groups at several times of
glycemic determination (isradipine: P
3207.p65 15/10/2004, 15:36247
248
REV. HOSP. CLÍN. FAC. MED. S. PAULO 59(5):244-250, 2004Glycemia in newborns of hypertensive mothers
Darcie S et al.
Figure 4 - Hypoglycemic episodes according
to lifetime.
Table 3 - Hypoglycemia episodes in each of the groups, according to the assessment
time point.
1st hour 3rd hour 6th hour 12nd hour 24th hour Total
ISRADIPINE 15 8 5 3 5 36
ATENOLOL 17 10 8 6 3 44
CONTROL 2 1 1 2 1 7
Total 34 19 14 11 9 87
Figure 5 - Hypoglycemic episodes distribu-
tions per groups.
Figure 6 - Number of newborns with hypo-
glycemia in each one of the groups.
<.001; atenolol: P <.001; control; P
<.01; Table 2). This finding is to be
expected, beginning with the differ-
ence observed between the maternal
glycemia and the umbilical cord, since
fetal plasma glucose levels at birth
have been reported to be two thirds of
maternal levels.20
Moreover, the evolution of
glycemic levels during the consecu-
tive time points of this study in each
group is consistent with the published
data, which show a reduction of the
plasma glucose concentration after
birth, reaching a nadir around 1 hour
postpartum followed by elevation and
stabilizing of levels between 2 and 4
hours after birth,20,21 as it may be ob-
served on Table 2 and in Figure 1. The
3 groups presented similar patterns,
having no significant differences
among themselves at each time point
of the assessments (Table 2).
In 1992, Kalhan20 referred to a lin-
ear relationship between maternal and
fetal glycemia, which is also evident
in the present study, since there was
correlation between maternal and um-
bilical cord glycemias in the
isradipine and control groups (Figures
2 and 3). In the control group, there
was also a correlation between glyc-
emia levels in the mother and in the
newborn at the third and sixth hours
postpartum, suggesting that there is a
tendency for maintaining the glycemia
at normal levels for a longer time, in
spite of the drop during the first hours
postpartum. This finding differs from
that of the isradipine group, where a
correlation of glycemia levels was
found only between the maternal and
umbilical cord blood. In the atenolol
group, there was no correlation of gly-
cemia levels at any time between the
mother and newborn. This finding may
suggest that atenolol has an earlier ef-
fect upon newborn glycemia than
isradipine does.
This observation, associated with
the presence of correlation at all time
points of assessment in the control
group, suggests that isradipine may
have an early effect upon newborn gly-
cemia, although a bit later than that of
atenolol.
The observation of more frequent
hypoglycemic episodes in the first and
third hours postpartum in all groups
(Figure 4, Table 3), agrees with the
well-known evolution of the glycemic
levels of the newborn during the first
hours after birth.20
There were more hypoglycemic
episodes in newborns of the atenolol
group than in the isradipine group, al-
though this was not statistically sig-
nificant (P = .818). However, the oc-
currence of hypoglycemia was signifi-
cantly higher in the atenolol group
compared with the control group,
which indicates its effects upon the
newborn glycemia. As for the
isradipine group compared with the
control group, there was a trend of the
occurrence of hypoglycemia, suggest-
ing a mild effect upon the newborn
glycemia (Figures 5 and 6).
The occurrence of hypoglycemia
also in newborns of mothers whose hy-
pertension was controlled with diet
only is consistent with the knowledge
of the effects of hypertensive disease
on the fetal glycemia. These effects in-
clude the reduction of uteroplacental
circulation, resulting in hypoxemia
that stimulates hormonal and circula-
tory effects with the redistribution of
the fetal blood flow and stimulation of
glycolysis (Pasteur effect), resulting in
an increase of triphosphate adenosine
(ATP) and lactic acid, in addition to
causing hypoglycemia.2 Besides that,
data that suggest a similarity between
3207.p65 15/10/2004, 15:36248
249
REV. HOSP. CLÍN. FAC. MED. S. PAULO 59(5):244-250, 2004 Glycemia in newborns of hypertensive mothers
Darcie S et al.
specific hypertensive disease of preg-
nancy and the resistance to insulin
syndrome are increasing in the medi-
cal literature: hyperinsulinemia, low
levels of high density lipoproteins
(HDL) and elevated levels of triglyc-
eride.23
After the analysis of these results,
some conclusions and consequent rec-
ommendations could be made:
- Different antihypertensive treat-
ment schemes used in pregnant
women (diet, isradipine, and
atenolol) have similar effects upon
mean values of glycemia in the
newborn;
- The correlation analysis suggests
that isradipine may have later and
milder effects upon the glycemia,
since the correlation was obtained
only in umbilical cord, while
atenolol may act earlier, since there
was no correlation in any time
point;
- The results reinforce the need for
glycemic control from the first
hour postpartum in newborns of hy-
pertensive mothers whether or not
they are undergoing drug treatment.
RESUMO
DARCIE S e col. Glicemia no recém-
nascido de mãe hipertensa de acor-
do com a terapêutica materna. Rev.
Hosp. Clín. Fac. Med. S. Paulo
59(5):244-250, 2004.
OBJETIVO: Avaliar o comporta-
mento da glicemia em recém-nascidos
(RN) de mães hipertensas conforme o
tratamento materno.
MÉTODOS: Estudo prospectivo,
randomizado, incluindo 93 RN de mães
tratadas com isradipina(n=39), atenolol
(n=40) ou dieta - controle (n=14). De-
terminou-se a glicemia ao nascimento
(mãe e RN, pela glicose oxidase) e na
1a., 3a., 6a., 12a. e 24a. horas (RN, por fita
reagente). A evolução da glicemia, em
cada grupo, foi analisada (Teste de
Friedman). Os grupos foram compara-
dos, quanto às glicemias, em cada mo-
mento (Teste de Kruskall-Wallis) e fo-
ram ajustados modelos de regressão li-
near para as glicemias (variável inde-
pendente = glicemia materna; variáveis
dependentes = glicemias de cordão, 3a.
e 6a. horas).
RESULTADOS: Não houve dife-
rença estatisticamente significante en-
tre as glicemias médias dos 3 grupos,
em qualquer uma das coletas. Houve
correlação entre as glicemias materna
e de cordão umbilical nos grupos
isradipina (r =0,61; p<0,05) e controle
(r =0,84; p<0,05); entre as glicemias
materna e 3a. e 6a. horas, houve ape-
nas no grupo controle (materna X
3a.hora: r = 0,65; p<0,05; materna X
6a.hora: r =0,68; p<0,05). Não houve
correlação em nenhum momento no
grupo atenolol. Detectou-se hipogli-
cemia em 51,3% (Isradipina), 60%
(Atenolol) e 35,7% (Controle), mais
freqüentemente na 1a. hora de vida, em
todos os grupos.
CONCLUSÕES: Os resultados su-
gerem efeito semelhante dos 3 tipos de
terapêutica sobre a glicemia do RN. As
análises de correlação sugerem que a
isradipina possa ter efeitos sobre a
glicemia somente após o nascimento
(correlação apenas em cordão umbili-
cal), enquanto o atenolol, possa atuar
mais precocemente (não se correla-
cionou em nenhum momento). Tam-
bém reforçam a necessidade de contro-
le glicêmico desde a 1a. hora de vida
em RN de mães hipertensas, submeti-
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